Earnings call transcript: Syndax Pharmaceuticals Q4 2025 revenue beats forecast, stock rises

Syndax beat Q4 2025 revenue expectations with $68.7M (8.82% above the $63.13M consensus) but missed EPS at -$0.78 versus a -$0.59 forecast (32.2% negative surprise). Revuforj ($44.2M, +38% Q/Q) and Niktimvo ($56M, +22% Q/Q) powered top-line momentum and the stock rose ~4.6% in after-hours (to $21.71) and reached $24.29 in the aftermarket. The company has a solid liquidity position ($394M cash, current ratio 4.4) and guided R&D+SG&A of ~ $400M for 2026 while stating an intent to reach profitability without new capital. Key risks to watch are the reported -54% gross margin and high expense run-rate; upcoming trial readouts and margin trends will be material for valuation and near-term upside.

Analysis

Commercial momentum is buying time for execution risk but also raises the stakes on durability: as treatment durations and post‑transplant maintenance stack, upside to lifetime revenue per patient is nonlinear, so small changes in average persistence (months → years) can drive outsized cash‑flow inflection. That dynamic magnifies the importance of real‑world evidence releases and frontline combination data as de‑risking catalysts — not mere volume metrics but proofs that duration and payor economics scale.

Margins and profitability are the real optionality engine. Scale should improve reported unit economics as in‑house net revenue replaces collaboration accounting and fixed SG&A dilutes, but this is conditional on durable pricing, growing in‑label use, and controlling COGS/gross‑to‑net leakage; failure on any of those (higher rebates, unexpected COGS, or rising discounting for combo regimens) flips the story fast. The fund’s exposure should therefore be calibrated to binary clinical/regulatory readouts over the next 12–36 months rather than steady‑state sales momentum alone.

Strategically, the biggest second‑order winners are commercialization partners and large cap biologics with complementary assets: any upside in the IPF program or frontline menin adoption will flow to partners and could accelerate M&A interest or licensing premium. The key risks are classic biotech binary outcomes — pivotal failures, regulatory delays, or payer pushback on expanded use — which would likely compress multiples sharply given elevated R&D/SG&A commitments and the valuation embedding clinical success across multiple programs.

Key Decisions for Investors

• SNDX — Tactical long with protection: initiate a modest directional position (1.5–3% NAV). Execute long equity or a 9‑month call spread to capture momentum, and simultaneously buy a 6–9 month 20–30% OTM put to cap downside from binary clinical/regulatory disappointment; reward if readouts/real‑world data sustain duration gains, downside limited to put cost plus equity exposure.
• SNDX — Options asymmetric: purchase a 9‑12 month bull call spread (cost‑defined) sized for 0.5–1% NAV targeting 2x–4x payoff if frontline/IPF catalysts are positive; this retains upside while limiting capital at risk against the multi‑quarter development pathway.
• INCY — Partner hedge / less‑binary exposure: add a small long position (1–2% NAV) or 12‑month call to capture upside from axatilimab commercialization and downstream label expansion. Rationale: partner benefits from any Niktimvo/axatilimab upside without shouldering the same development burn; downside is lower volatility versus single‑asset SNDX exposure.
• SNDX — Protective short tail hedge: buy a 9‑12 month SNDX put spread (bear put) sized to offset 25–40% of the long holding’s notional to protect against trial or reimbursement failure. Use this rather than outright short to avoid margin and unlimited risk while monetizing the pronounced binary downside.